US2006182732A1PendingUtilityA1

Composition for mitigating a pernicious thrombotic event

53
Individually held — no corporate assignee on recordPriority: Jul 23, 2003Filed: Mar 28, 2006Published: Aug 17, 2006
Est. expiryJul 23, 2023(expired)· nominal 20-yr term from priority
Inventors:Arnold Nerenberg
A61K 31/60A61K 38/482A61K 33/06
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition. The composition comprises aspirin, magnesium, and nattokinase, and either niacin or nitroglycerine. The composition has a structural form of: a chewable form, a dissolvable form, a liquid form, a spray form, or a suppository form. The structural form is suitable for being introduced into the body of a person, such as by means of a body cavity of the person. The composition may be used for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event, such as a heart attack or stroke, in the person.

Claims

exact text as granted — not AI-modified
1 . A composition, comprising nattokinase and at least one of aspirin, magnesium, and a blood vessel dilator, said blood vessel dilator being either niacin or nitroglycerine, said composition having a structural form that is suitable for being introduced into a body of a person.  
   
   
       2 . The composition of  claim 1 , wherein the nattokinase and the at least one of aspirin, magnesium, and the blood vessel dilator each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event in the person.  
   
   
       3 . The composition of  claim 2 , wherein the pernicious thrombotic event in the person is a heart attack or stroke in the person.  
   
   
       4 . The composition of  claim 1 , wherein the nattokinase has an amount in a range of 150 to 3000 mg.  
   
   
       5 . The composition of  claim 1 , wherein the composition comprises aspirin.  
   
   
       6 . The composition of  claim 1 , wherein the composition comprises magnesium.  
   
   
       7 . The composition of  claim 1 , wherein the composition comprises niacin.  
   
   
       8 . The composition of  claim 1 , wherein the composition comprises nitroglycerine.  
   
   
       9 . The composition of  claim 1 , wherein the composition comprises at least two of aspirin, magnesium, and the blood vessel dilator.  
   
   
       10 . The composition of  claim 11 , wherein the composition comprises aspirin and magnesium.  
   
   
       11 . The composition of  claim 11 , wherein the composition comprises aspirin and the blood vessel dilator.  
   
   
       12 . The composition of  claim 11 , wherein the composition comprises magnesium and the blood vessel dilator.  
   
   
       13 . The composition of  claim 1 , wherein the composition further comprises L-carnitine.  
   
   
       14 . The composition of  claim 1 , wherein the composition further comprises alpha lipoic acid.  
   
   
       15 . The composition of  claim 1 , wherein the composition further comprises L-arginine.  
   
   
       16 . The composition of  claim 1 , wherein the composition further comprises coenzyme Q10.  
   
   
       17 . A method, comprising introducing a composition into a person, wherein the composition comprises nattokinase and at least one of aspirin, magnesium, and a blood vessel dilator, wherein the blood vessel dilator is either niacin or nitroglycerine, and wherein the nattokinase and the at least one of aspirin, magnesium, and the blood vessel dilator each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring-pernicious thrombotic event in the person.  
   
   
       18 . The method of  claim 17 , wherein the pernicious thrombotic event in the person is a heart attack or stroke in the person.  
   
   
       19 . The method of  claim 17 , wherein the nattokinase has an amount in a range of 150 to 3000 mg.  
   
   
       20 . The method of  claim 17 , wherein the composition comprises aspirin.  
   
   
       21 . The method of  claim 17 , wherein the composition comprises magnesium.  
   
   
       22 . The method of  claim 17 , wherein the composition comprises niacin.  
   
   
       23 . The method of  claim 18 , wherein the composition comprises nitroglycerine.  
   
   
       24 . The method of  claim 17 , wherein the composition comprises at least two of aspirin, magnesium, and the blood vessel dilator.  
   
   
       25 . The method of  claim 24 , wherein the composition comprises aspirin and magnesium.  
   
   
       26 . The method of  claim 24 , wherein the composition comprises aspirin and the blood vessel dilator.  
   
   
       27 . The method of  claim 24 , wherein the composition comprises magnesium and the blood vessel dilator.  
   
   
       28 . The method of  claim 17 , wherein the composition further comprises L-carnitine.  
   
   
       29 . The method of  claim 17 , wherein the composition further comprises alpha lipoic acid.  
   
   
       30 . The method of  claim 17 , wherein the composition further comprises L-arginine.  
   
   
       31 . The method of  claim 17 , wherein the composition further comprises coenzyme Q10.  
   
   
       32 . A method, comprising introducing a composition into a person, wherein the composition comprises aspirin, magnesium, nattokinase, and a blood vessel dilator, wherein the blood vessel dilator is either niacin or nitroglycerine, and wherein the aspirin, magnesium, nattokinase, and the blood vessel dilator each have a therapeutically effective amount for mitigating adverse effects of an imminent or actually-occurring pernicious thrombotic event in the person.  
   
   
       33 . The method of  claim 32 , wherein the pernicious thrombotic event in the person is a heart attack or stroke in the person.  
   
   
       34 . The method of  claim 32 , wherein the nattokinase has an amount in a range of 150 to 3000 mg.  
   
   
       35 . The method of  claim 34 , wherein the composition further comprises L-carnitine.  
   
   
       36 . The method of  claim 34 , wherein the composition further comprises alpha lipoic acid.  
   
   
       37 . The method of  claim 34 , wherein the composition further comprises L-arginine.  
   
   
       38 . The method of  claim 34 , wherein the composition further comprises coenzyme Q10.

Join the waitlist — get patent alerts

Track US2006182732A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.